TORONTO — October 27, 2025 Leads & Copy — BriaCell Therapeutics Corp. (TSX:BCT, Nasdaq:BCTX) gained 13 percent this week after announcing an expansion of its Phase 2 trial for Bria-IMT™, a personalized immunotherapy targeting advanced breast cancer.
The Toronto-based biotech will add 40 patients to the study following interim results showing tumor shrinkage and improved progression-free survival. The company also received FDA Fast Track designation, accelerating its regulatory timeline.
CEO William Williams said BriaCell is in talks with potential commercial partners and plans to present updated data at the American Society of Clinical Oncology meeting in early 2026.
BriaCell shares are up 36 percent this quarter, driven by investor confidence in its immuno-oncology platform.
